The content on this site is intended for healthcare professionals only
Dr Arend von Stackelberg speaks to ecancer about a talk he gave at the recent ALL Assembly 2021 meeting on 'safety profile of BiTE therapy'.
He explains how blinatumomab, a type of BiTE (bispecific T-cell engager), functions in the body to destroy leukaemia cells and how adverse events can occur.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
